French biotech Pharnext has seen the value of its shares collapse after it revealed that its lead drug, a treatment for Charcot-Marie-Tooth (CMT) disease, failed to make the grade in a phase 3 trial.

After decades of stagnation in the drug treatment of schizophrenia, a handful of new therapies have raised hopes of improvement – but one of them has just failed a pair of phase 3 trials. Sumitomo ...

Debugging in Python can transform from a dreaded task into a powerful way to understand and improve your code. With tools like PyCharm’s visual debugger, pdb’s command-line control, and structured ...

Anthropic has launched AI connectors integrating Claude with major creative and design platforms, while Xbox introduced its ...

With the rapid expansion of the new energy vehicle (NEV) market, charging and battery swapping have emerged as the two ...